A randomized, double-blind, placebo-controlled clinical study to assess safety and clinical activity of OTO-104 given as a single intratympanic injection in patients with unilateral Ménière's disease

Otology and Neurotology

Volumn 33, Issue 7, 2012, Pages 1257-1265

  Lambert, Paul R ^a   Nguyen, Shaun ^a   Maxwell, Kenneth S ^b   Tucci, Debara L ^c   Lustig, Lawrence R ^d   Fletcher, Malcolm ^e   Bear, Moraye ^f   Lebel, Carl ^g  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Piedmont Ear Nose and Throat Associates   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e SYNEOS HEALTH   (United States)

^f Forsythe and Bear LLC   (United States)

^g Otonomy Inc   (United States)

Author keywords

Corticosteroid; Dexamethasone; Double blind; Intratympanic; M ni re's disease; M ni re's disease patientoriented symptom severity index; Tinnitus; Tinnitus Handicap Inventory; Vertigo

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; PLACEBO;

ADULT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; EARDRUM; FEMALE; HUMAN; MALE; MENIERE DISEASE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERTIGO;

ADULT; AGED; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MENIERE DISEASE; MIDDLE AGED; PLACEBOS; TREATMENT OUTCOME; TYMPANIC MEMBRANE; VERTIGO;

EID: 84865584394     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e318263d35d     Document Type: Article

References (30)

1. Barritt L. Ménière's disease. XPharm 2008;3:1-6.
2. Committee on Hearing and Equilibrium. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Ménière's disease. Otolaryngol Head Neck Surg 1995;113:181-5.
3. Anderson JP, Harris JP. Impact of Ménière's disease on quality of life. Otol Neurotol 2001;22:888-94.
4. Gupta BBP, Lalchhandama K. Molecular mechanisms of glucocorticoid action. Curr Sci 2002;83:1103-11.
5. Silverstein H, Farrugia M, Van Ess M. Dexamethasone inner ear perfusion for subclinical endolymphatic hydrops. Ear Nose Throat J 2009;88:778-85.
6. Garduño-Anaya MA, Couthino De Toledo H, Hinojosa-González R, Pane-Pianese C, Ríos-Castañeda LC. Dexamethasone inner ear perfusion by intratympanic injection in unilateral Ménière's disease: a two-year prospective, placebo-controlled, double-blind, randomized trial. Otolaryngol Head Neck Surg 2005;33:285-94.
7. Arriaga MA, Goldman S. Hearing results of intratympanic steroid treatment of endolymphatic hydrops. Laryngoscope 1998;108: 1682-85.
8. Barrs DM, Keyser JS, Stallworth C, McElveen JT Jr. Intratympanic steroid injections for intractable Ménière's disease. Laryngoscope 2001;111:2100-4.
9. Boleas-Aguirre MS, Lin FR, Della Santina CC, Minor LB, Carey JP. Longitudinal results with intratympanic dexamethasone in the treatment of Ménière's disease. Otol Neurotol 2008;29:33-8.
10. Hirvonen TP, Peltomaa M, Ylikoski J. Intratympanic and systemic dexamethasone for Ménière's disease. ORL J Otorhinolaryngol Relat Spec 2000;62:117-20.
11. Sennaroglu L, Sennaroglu G, Gursel B, Dini FM. Intratympanic dexamethasone, intratympanic gentamicin, and endolymphatic sac surgery for intractable vertigo in Ménière's disease. Otolaryngol Head Neck Surg 2001;125:537-43.
12. Silverstein H, Isaacson JE, Olds MJ, Rowan PT, Rosenberg S. Dexamethasone inner ear perfusion for the treatment of Ménière's disease: a prospective, randomized, double-blind, crossover trial. Am J Otol 1998;19:196-201.
13. Piu F, Wang X, Fernandez R, et al. OTO-104: a sustained-release dexamethasone hydrogel for the treatment of otic disorders. Otol Neurotol 2011;32:171-9.
14. Thornton AR, Raffin MJM. Speech-discrimination scores modeled as a binomial variable. J Speech Lang Hear Res 1978;21:507-18.
15. Gates GA, Verrall A, Green JD Jr, Tucci DL, Telian SA. Meniett clinical trial: long-term follow-up. Arch Otolaryngol Head Neck Surg 2006;132:1311-16.
16. Gates GA, Green JD, Tucci DL, Telian SA. The effects of transtympanic micropressure treatment in people with unilateral Ménière's disease. Arch Otolaryngol Head Neck Surg 2004;130:718-25.
17. Gates GA. Clinimetrics of Ménière's disease. Laryngoscope 2000; 110:8-11.
18. Fitzmaurice GM., Laird NM, Ware JH. Applied Longitudinal Analysis. New York, NY: John Wiley & Sons, 2004.
19. Buckingham JC. Glucocorticoids: exemplars of multi-tasking. Br J Pharmacol 2006;147:258-68.
20. Haake SM, Dinh CT, Chen S, Eshraghi AA, Van De Water TR. Dexamethasone protects auditory hair cells against TNFalphainitiated apoptosis via activation of PI3K/Akt and NFJB signaling. 255:22-32.
21. Herman P, Tan CT, van den Abbeele T, Escoubet B, Friedlander G, Huy PT. Glucocorticoids increase sodium transport in middle ear epithelium. Am J Physiol 1997;272:C184-90.
22. Kim SH, Kim KX, Raveendran NN, Wu T, Pondugula SR, Marcus DC. Regulation of ENaC-mediated sodium transport by glucocorticoids in Reissner's membrane epithelium. Am J Physiol Cell Physiol 2009;296:C544-57.
23. Dinh CT, Bas E, Chan SS, Vu L, Van De Water TR. Dexamethasone treatment of tumor necrosis factor-alpha challenged organ of Corti explants activates nuclear factor kappa B signaling that induces changes in gene expression that favor hair cell survival. Neuroscience 2011; 188:157-67.
24. Araujo MF, Oliveira CA, Bahmad FM Jr. Intratympanic dexamethasone injections as a treatment for severe, disabling tinnitus: does it work? Arch Otolaryngol Head Neck Surg 2005;131:113-7.
25. Kitahara T, Kubo T, Okumura S, Kitahara M. Effects of endolymphatic sac drainage with steroids for intractable Ménière's disease: a long-term follow-up and randomized controlled study. Laryngoscope 2008;118:854-61.
26. Bird PA, Begg EJ, Zhang M, Keast AT, Murray DP, Balkany TJ. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007;28:1124-30.
27. Rauch SD, Halpin CF, Antonelli PJ, et al. Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA 2011;305:2071-79.
28. Herraiz C, Plaza G, Aparicio JM, et al. Transtympanic steroids for Ménière's disease. Otol Neurotol 2010;31:162-7.
29. Muehlmeier G, Biesinger E, Maier H. Safety of intratympanic injection of AM-101 in patients with acute inner ear tinnitus. Audiol Neurotol 2011;16:388-97.
30. Bird PA, Murray DP, Zhang M, Begg EJ. Intratympanic versus intravenous delivery of dexamethasone and dexamethasone sodium phosphate to cochlear perilymph. Otol Neurotol 2011;32: 933-6.